InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,480.10
(
0.28%
)
US TECH 100
19,162.00
(
-0.24%
)
Dow Jones
39,501.94
(
0.90%
)
Brent Oil
84.85
(
0.98%
)
Bitcoin
61,283.85
(
-2.97%
)
Post# of 252316
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 25
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: ghmm post# 110545

Thursday, 12/09/2010 4:46:02 PM

Thursday, December 09, 2010 4:46:02 PM

Post# of 252316
slides on ocrelizumab are interesting.. it looks like they are going after PPMS as well as RRMS..


Can someone post slide 92 on IHUB. Dew? This show the RRMS relapse reduction rates across all MS therapies, those on the market and in ph2/3.

Interestingly, ocrelizumab has the best efficacy, although we all know you can't make direct comparisons :)
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up